Navigation Links
CareFusion Reports First Half Fiscal 2013 Results
Date:2/7/2013

continuing operations in the second quarter of $108 million, or $0.48 per diluted share. Adjusted income from continuing operations increased 9 percent from the prior year period to $121 million, or $0.54 per diluted share. The adjusted tax rate was 29.6 percent for the second quarter.

Medical SystemsSecond quarter revenue for the Medical Systems business segment of $602 million on a reported and constant currency basis was nearly even with the prior year period. Results were driven primarily by an expected decrease in the Infusion Systems business. Despite the year-over-year decline, Infusion Systems performed ahead of company expectations.

Segment profit increased 7 percent from the prior year period to $123 million, as gross margin improvements and SG&A leverage helped to fund increased investments in R&D. Adjusted segment profit was $134 million, an increase of 2 percent from the prior year period.

Procedural SolutionsSecond quarter revenue for the Procedural Solutions business segment increased 7 percent from the prior year period to $307 million on a reported and constant currency basis. The increase was driven by strong performance across all three business units, with continuing growth in Infection Prevention, Medical Specialties delivering its highest revenue growth in more than two years and Specialty Disposables benefitting from an early start to the flu season.

This top-line strength carried through to the bottom line, with segment profit increasing 71 percent from the prior year period to $48 million. Adjusted segment profit was $55 million, a 45 percent increase driven by strength in the company's clinically differentiated portfolio and disciplined expense management efforts.

Six-Month ResultsFor the first six months of fiscal 2013, revenue increased 2 percent from the prior year period to $1.75 billion. Operating income increased to $314 million from $258
'/>"/>

SOURCE CareFusion Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
2. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
3. CareFusion Expands Infusion Pump Interoperability
4. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
5. CareFusion Reports Fourth Quarter and Fiscal 2012 Results
6. CareFusion Recognizes Best Of The Best U.S. Hospitals
7. CareFusion Provides Update On Form 10-K Filing
8. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
9. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
10. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
11. CareFusion Files Fiscal 2012 Form 10-K
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/22/2014)... This news release is available in German . ... species are important intracellular signaling molecules, but their mode ... key aspects of cellular function and behavior, while at ... organelles, membranes and DNA. To analyze how redox signaling ... innovative optical microscopy technique has been developed jointly by ...
(Date:4/22/2014)... 7 in 10 Americans support mandated coverage of birth ... researchers at the University of Michigan Health System. , ... of 18 at home, and adults with private or ... to support universal coverage of birth control medications, according ... of the American Medical Association ( JAMA ). ...
(Date:4/22/2014)... alfa (trade name: NovoEight) has been approved since November ... patients with haemophilia A. In an early benefit assessment ... Market for Medicinal Products" (AMNOG), the German Institute for ... this new active ingredient offers an added benefit over ... findings, an added benefit of turoctocog alfa is not ...
(Date:4/22/2014)... Cedars-Sinai stroke intervention researchers have been informed that ... of the National Institutes of Health, will award an ... clinical trial of an experimental drug for stroke. ... with recombinant tissue plasminogen activator, or rtPA the ... after onset. In laboratory rodent studies, 3K3A-APC, used in ...
(Date:4/22/2014)... have found that the anxiety experienced with a ... impact a woman,s overall well-being. Their findings are ... was published online in the April 21, 2014 ... 40 to 60 percent of women who undergo ... experience a false-positive mammogram. Such mammograms require additional ...
Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2
... cholesterol-lowering statins were significantly less likely to develop depression than ... MD, a physician at the San Francisco VA Medical Center ... San Francisco. The study was published electronically in the ... Whooley and her research team evaluated 965 heart disease patients ...
... News) -- Many young children from low-income families drink too ... and tooth decay, the American Academy of Pediatrics recommends children ... -- even 100 percent fruit juice -- each day. In ... on Children,s Health, however, it was found that about 50 ...
... c-MET expression in tumors., Invasion and metastasis were blocked ... are in late-stage clinical trials. PHILADELPHIA ... signaling inhibited tumor invasion and metastasis in a laboratory ... published in Cancer Discovery , the newest journal ...
... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... in overweight and obese women as those of normal ... females, a group of reproductive experts said. During ... Federation of America and the Society of Family Planning, ...
... generate a lot of internal debris that can trigger the ... as lupus., Now Georgia Health Sciences University researchers report that ... from attacking a fetus also helps block development of these ... joints. , The findings point toward new treatment strategies ...
... THURSDAY, Feb. 23 (HealthDay News) Compared to other ... in elderly patients with dementia, a new study finds. ... in dementia care. "This data provides much-needed guidance and ... treating older demented patients," said Dr. Gisele Wolf-Klein, director ...
Cached Medicine News:Health News:Statins linked with lower depression risk in heart patients 2Health News:Kids From Poorer Families Drink Too Much Juice: Poll 2Health News:Combined inhibition of VEGF and c-MET can decrease metastasis 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 3Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3Health News:Certain Antipsychotics Up Risk of Death for Patients With Dementia: Study 2
... Established in 1939, AMT has become ... agencies for clinical laboratory practitioners and ... certification for Medical Technologists, Medical Laboratory ... Phlebotomy Technicians, Medical and Dental Assistants ...
... Proficiency Testing and Quality Assurance (for Waived ... assist POLs, clinics and small hospitals maintain ... accuracy of patient lab results and assist ... the opportunity to earn 12 P.A.C.E. Contact ...
An enzyme linked immunosorbent assay (ELISA) for the detection and quantitationof RF IgG isotype in human serum of patients with rheumatoid arthritis....
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
Medicine Products: